Study population by gender and country
| CALIBER (England) | PREDICT (New Zealand) | |||||
|---|---|---|---|---|---|---|
| Characteristics | Women | Men | Overall | Women | Men | Overall |
| N patients | 401 997 | 284 478 | 686 475 | 86 084 | 108 429 | 194 513 |
| Age in years, median (IQR) | 49 (39, 60) | 52 (42, 61) | 50 (40, 60) | 57 (50, 63) | 52 (46, 60) | 55 (47, 62) |
| N (%) with white cell count record* | 401 997 (100%) | 284 478 (100%) | 686 475 (100%) | 63 880 (74.2%) | 75 150 (69.3%) | 139 030 (71.5%) |
| White cell count (×109/L), median (IQR) | 6.7 (5.5, 8.1) | 6.6 (5.5, 8.0) | 6.6 (5.5, 8.1) | 6.6 (5.4, 8.0) | 6.7 (5.6, 8.1) | 6.6 (5.5, 8.0) |
| Ethnicity | ||||||
| N (%) with ethnicity recorded | 256 726 (63.9%) | 160 102 (56.3%) | 416 828 (60.7%) | 86 084 (100%) | 108 429 (100%) | 194 513 (100%) |
| White (CALIBER)/European (PREDICT) | 235 140 (91.6%) | 148 288 (92.6%) | 383 428 (92.0%) | 45 462 (52.8%) | 58 538 (54.0%) | 104 000 (53.5%) |
| South Asian (CALIBER)/Indian (PREDICT) | 8140 (3.2%) | 4810 (3.0%) | 12 950 (3.1%) | 6811 (7.9%) | 9506 (8.8%) | 16 317 (8.4%) |
| Pacific (PREDICT) | – | – | – | 12 810 (14.9%) | 15 754 (14.5%) | 28 564 (14.7%) |
| Māori (PREDICT) | – | – | – | 12 193 (14.2%) | 13 777 (12.7%) | 25 970 (13.4%) |
| Asian (PREDICT) | – | – | – | 7306 (8.5%) | 8570 (7.9%) | 15 876 (8.2%) |
| Black (CALIBER) | 6373 (2.5%) | 3261 (2.0%) | 9634 (2.3%) | – | – | – |
| Other | 7073 (2.8%) | 3743 (2.3%) | 10 816 (2.6%) | 1502 (1.7%) | 2284 (2.1%) | 3786 (2.0%) |
| Current smoker, n (%)† | 87 540/385 575 (22.7%) | 74 003/268 766 (27.5%) | 161 543/654 341 (24.7%) | 12 275/86 084 (14.3%) | 19 518/108 429 (18.0%) | 31 793/194 513 (16.4%) |
| Systolic blood pressure in mm Hg, median (IQR)† | 130 (119, 144) | 140 (128, 150) | 134 (120, 148) | 130 (120, 140) | 130 (120, 140) | 130 (120, 140) |
| Total:HDL cholesterol ratio, median (IQR)† | 3.6 (2.9, 4.5) | 4.4 (3.5, 5.3) | 4.0 (3.2, 4.9) | 3.6 (2.9, 4.4) | 4.3 (3.5, 5.2) | 4.0 (3.2, 4.9) |
| Diabetes at baseline, n (%) | 12 741 (3.2%) | 16 219 (5.7%) | 28 960 (4.2%) | 7764 (9.0%) | 8882 (8.2%) | 16 646 (8.6%) |
| Deaths during follow-up, n (%) | 9636 (2.4%) | 9961 (3.5%) | 19 597 (2.9%) | 892 (1.0%) | 1338 (1.2%) | 2230 (1.1%) |
| Follow-up time (years), median (IQR) | 4.21 (1.96, 6.42) | 3.75 (1.73, 5.97) | 4.01 (1.86, 6.23) | 2.23 (0.98, 3.78) | 2.21 (0.99, 3.86) | 2.22 (0.99, 3.83) |
| Year of enrolment, % | ||||||
| 1998–2004 | 48.6% | 42.6% | 46.1% | 0 | 0 | 0 |
| 2005–2008 | 40.9% | 45.1% | 42.6% | 40.5% | 31.7% | 36.0% |
| 2009–2010 | 10.6% | 12.3% | 11.3% | 28.2% | 43.9% | 36.3% |
| 2011–2012 | 0 | 0 | 0 | 31.4% | 24.4% | 27.8% |
*In PREDICT, we used the most recent total white cell count within 5 years prior to 2 weeks after the cardiovascular risk assessment. In CALIBER, the study start date was the date of the white cell count measurement, and patients without any white cell count measurement were excluded.
†In CALIBER, we used the most recent blood pressure and cholesterol measurements within 1 year prior to study entry. Blood pressure was available in 63.8% of people, total cholesterol in 32.0% and smoking status in 95.3%. In PREDICT, these measurements were taken at the time of the cardiovascular risk assessment, and were completely recorded.
CALIBER, ClinicAl research using LInked Bespoke studies and Electronic health Records; HDL, high-density lipoprotein.